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To identify serum biomarkers that allow monitoring of disease progression and treatment eﬀects in Duchenne muscular dystrophy
(DMD) patients, levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase-1 (TIMP-1) and osteopontin
(OPN) were determined in 63 DMD patients on corticosteroid therapy. These proteins were selected for their role in the pathogenesis
of muscular dystrophy. Levels of MMP-9 and TIMP-1 were signiﬁcantly higher in sera of DMD patients compared to healthy controls,
whereas the OPN levels showed no signiﬁcant diﬀerence. MMP-9 levels were also observed to be signiﬁcantly higher in older, nonamb-
ulant patients, compared to ambulant patients. Longitudinal data from a smaller cohort of DMD patients followed up for over 4 years
showed that MMP-9, but not TIMP-1 increased signiﬁcantly with age. Hence, MMP-9 is a potential DMD biomarker for disease pro-
gression. Future studies have to conﬁrm whether serum MMP-9 levels can be used to monitor therapeutic response.
 2011 Elsevier B.V.
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Clinical biomarkers can be used to diagnose, monitor
aetiology and progression of diseases and guide therapeutic
decisions [1]. The serum biomarker currently used primar-
ily as a ﬁrst diagnostic hint for Duchenne muscular dystro-
phy (DMD), is creatine kinase (CK), where high levels of
CK reﬂect muscle damage and/or disease. There are, how-
ever, several drawbacks to the CK test: levels may fall when0960-8966  2011 Elsevier B.V.
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[2], and CK levels are also increased in normal individuals
due to exercise, exertion or trauma to the skeletal muscle.
Other available tests to monitor the progression of DMD
pathology have limitations as well. Muscle biopsies have
diagnostic value, but are laborious and invasive, and pro-
vide only local information on muscle quality, which may
not be reﬂective for the state of all muscles. Muscle
strength assessments are less of a burden to the patient
and have prognostic applications, but are subject to exten-
sive intra- and inter-patient variability [3]. As such, there is
no single test that can be used for diagnosis, prognosis, the
recognition and/or prediction of potential complications
and response to treatment. However, it might be feasible to
achieve this with a group of serum biomarkers. Considering
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for DMD [4–7], the identiﬁcation of serum biomarkers to
assess the eﬀect of these treatments would be invaluable,
since functional improvement cannot be expected within
the short treatment periods in early phase clinical trials,
and monitoring through repetitive muscle biopsies is not
feasible for longer trials.
Based on recent literature ﬁndings on the pathophysiol-
ogy of dystrophinopathy in both men and mice (dystrophin
deﬁcient mouse, mdx) via gene expression analyses [8–11],
we selected several potential serum biomarkers for DMD:
matrix metalloproteinase 9 (MMP-9), tissue inhibitor of
metalloproteinase (TIMP-1) and osteopontin (OPN).
MMP-9 is associated with the degradation or remodelling
of the extracellular matrix and is either secreted or present
as a trans-membrane proenzyme. It has recently been dem-
onstrated that Mmp9 gene expression is increased in mdx
mice and inhibition of Mmp9 reduces skeletal muscle dam-
age, inﬂammation, necrosis and ﬁbrosis [8]. This implies that
the absence ofMMP-9 inmdxmice reduces the eﬀects of dys-
trophin deﬁciency in the skeletal muscle. The proteolytic
activity of MMP-9 is modulated by TIMPs and it has been
postulated that the maintenance of the balance between
MMP-9 and TIMPs is essential to maintain tissue integrity
[12]. Gene expression analysis of mdx and DMD muscles
showed an upregulation of the TIMP1 gene [7,8] suggesting
it is worthwhile to include TIMP-1 in our biomarker study.
OPN, a phosphorylated glycoprotein of the bone, is also
expressed in immune cells, skin and blood vessels. The func-
tions of OPN include formation of collagen ﬁbrils during tis-
sue remodelling, promotion of macrophage and neutrophil
migration, angiogenesis and wound healing [11]. A recent
study revealed thatmdxmice have high OPN serum concen-
trations, while absence of the OPN encoding Spp1 gene in
mice reduced neutrophils and decreasedTGF-b levels result-
ing in reduced ﬁbrosis inmdxmice [11]. Interestingly, studies
on gene expression proﬁles of DMD muscles at various
stages of the disease also demonstrated signiﬁcant upregula-
tion of SPP1 [9,13–15].
The three selected biomarkers are suggested to have a
role either in inﬂammation, ﬁbrosis, or extracellular
matrix degradation, which are key events in the patho-
genesis of DMD. We hypothesize that these biomarkers
will be elevated in the DMD sera since DMD muscle
ﬁbres are leaky and continuously degenerating. Further-
more, as these markers are indicative for the disease
pathophysiology, we suggest that they have potential as
prognostic biomarkers. Our study examined serum levels
of the selected biomarkers in mdx mice and in sera of
corticosteroid treated DMD patients. The animal and
patient studies reinforced each other, as mouse studies
are better controlled but cannot be directly extrapolated
to humans. Based on comparisons with control samples
and correlations with other patient information, we sug-
gest that MMP-9 and TIMP-1 in combination can be
used as potential biomarkers for monitoring disease pro-
gression in DMD.2. Methods
2.1. Mice
Four week old C57BL/10ScSnJ (wt) (N = 5) and
C57BL/10ScSn-mdx/J (mdx) (N = 6) females were sub-
jected to forced exercise consisting of three times a week
horizontal treadmill running at 12 m/min for 30 min for
duration of 12 weeks to augment the severity of disease
[16]. Blood was collected at the age of 8 and 14 weeks via
the tail vein, allowed to clot at room temperature for
10 min and then spun at 1700 g for 10 min at 4 C before
pipetting the serum for storage at 80 C, prior to use.
For CK determination blood from the tail vein was col-
lected in a Minicollect tube (0.8 ml Lithium Heparin Sep,
Greiner bio-one, Austria). All mice were sacriﬁced at the
age of 16 weeks by cervical dislocation. The quadriceps
muscle was isolated, snap frozen in isopenthane, cooled
in liquid nitrogen and stored at 80 C. Quadriceps mus-
cles from nonexercised mdx mice were used as controls
for the gene expression studies. All experiments were
approved by the Institutional Animal Experimental Com-
mission (DEC) at LUMC.
2.2. Study participants
Sixty-three male patients with a molecular diagnosis of
DMD were recruited for this study from the clinic popula-
tion of the muscle service in Newcastle upon Tyne (mean
age 13.1 years, age range between 2.9 and 31.2 years). As
shown in Table 1, 34 of the patients were ambulant, with
a mean age of 8.7 years and 29 were nonambulant, with
a mean age of 18.1 years. Other clinical information such
as duration of corticosteroid therapy and North Star
Ambulatory Assessment (NSAA) scores were also avail-
able for these patients. Patients were on corticosteroid ther-
apy for an average of 3.2 years and the mean NSAA score
(available only for 29 ambulant patients) was 23/34.
Nine of the boys were followed up in a longitudinal
study involving blood sampling at various time intervals
[17]. They were on corticosteroid therapy, commenced at
a dose of 0.75 mg/kg/day of prednisolone as per interna-
tional guidelines [18]. Child D8 was on deﬂazacort prior
to and for the duration of the study due to unacceptable
side eﬀects from prednisolone (Table 2). The characteristics
of the nine boys are summarised in Table 2, as the type of
mutation, age of the boys, duration of corticosteroid treat-
ment and the North Star Ambulatory Scores (NSAA) were
also documented.
As part of the study four adult males (age range,
29.6–5.3 years; mean 32.4 years) and 12 healthy male chil-
dren (age range, 6.25–1.9 years; mean 8.2 years) were
recruited as controls. The healthy adult males (N = 4) were
working at the Institute of Human Genetics when recruited.
The control childrenwere attending theRoyal Victoria Inﬁr-
mary, Newcastle upon Tyne for venepuncture for renal
isotope imaging after a urinary tract infection. Any child
Table 1
Clinical parameters of the independent DMD patient cohort.
Age Years on corticosteroid therapy NSAA scores
Total DMD (N = 63) 13.10 ± 6.2 (2.9–31.2) 3.2 ± 3 (0–11.75) 23.33 ± 8.1# (3–33)
Ambulant (N = 34) 8.7 ± 3.3 (2.9–17.10) 2.7 ± 2.3 (0–7.5) 23.33 ± 8.1# (3–33)
Nonambulant (N = 29) 18.1 ± 4.6 (9.9–31.2) 3.8 ± 3.6 (0–11.5) not available
±Std. deviation; () minimum and maximum values.
Table 2
Clinical parameters of the longitudinal DMD patient cohort.
Patient Mutation (del exon) Visit Age NSAA scores Years on corticosteroid therapy
D1 47–50 1 9.40 26.00 3.25
D1 2 10.30 22.00 4.16
D1 3 11.00 11.00 4.83
D1 4 13.80 2.00 7.7
D2 53 1 9.25 32.00 3.16
D2 2 10.00 32.00 3.91
D2 3 10.80 27.00 4.83
D2 4 13.40 16.00 7.3
D3 52 1 6.40 – 0.83
D3 2 7.40 13.00 1.83
D3 3 8.10 8.00 2.5
D3 4 10.80 – 2.5
D5 52 1 7.25 22.00 0.41
D5 2 8.00 21.00 1.16
D5 3 11.25 11.00 4.35
D6 5–29 1 9.10 8.00 2.91
D6 2 9.80 10.00 3.67
D6 3 10.60 – 4.42
D6 4 13.10 – 6.85
D8 41–43 1 10.00 29.00 3.17
D8 2 10.60 29.00 3.83
D8 3 11.30 19.00 4.58
D8 4 13.80 23.00 7.2
D9 51 1 8.60 20.00 2.75
D9 2 9.30 15.00 3.50
D9 3 12.30 6.00 6.70
D10 42 Frames shift 1 6.73 27.00 2.17
D10 2 7.60 27.00 3.00
D10 3 10.00 24.00 5.60
D11 41 Nonsense 1 6.50 34.00 1.67
D11 2 7.30 33.00 2.50
Mean ± std. dev. 9.79 ± 2.12 20.25 ± 9.18 3.78 ± 1.92
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quently excluded from the study. Informed consent was
taken from the parents after a further discussion of the study
with both parents and child. The control children had no sig-
niﬁcant medical disorders and were not on any systemic
medication. All elements of the human study received a
favourable opinion from the local Research Ethics Commit-
tee prior to commencement.2.3. Human serum samples
Blood was taken from DMD and control groups by the
following method: 3–5 ml of venous blood (obtained prior
to radioisotope injection for the child controls) was drawn
and placed in BD-Vacutainer (367694) tubes. The bloodwas allowed to clot at room temperature for 10 min and
then placed in a refrigerator at 4 C before further spinning
at 2800 g at room temperature for 10 min. The serum
supernatant was carefully removed and aliquoted for stor-
age at 80 C pending use.2.4. RNA isolation and RT-PCR analysis
Total RNA of the quadriceps was isolated in Magna
Lyser Green Beads tubes (Roche diagnostics Ltd., UK)
using RNA-Bee (Tel-Test, Bio-Connect, Huissen, The
Netherlands) and puriﬁed with the NucleoSpin RNA II
kit (Bioke, The Netherlands). The RNA concentration
was measured on a Nanodrop (Nanodrop Technologies,
DE, USA) and integrity was checked with a lab-on-chip
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Netherlands). cDNA was generated and gene expression
levels were determined forMmp9, Timp1 and Spp1 (primer
sequences available on request) by Syber Green based Real
Time qPCR (95 C 10 s, 60 C 30 s, 72 C 20 s, 45 cycles)
on the Roche Lightcycler 480. Gapdh was used as a refer-
ence gene, since the expression of this gene did not diﬀer
between diﬀerent muscles or over time. The Cp values were
obtained with the second derivative maximum method and
analysed with genex (http://www.gene-quantiﬁcation.com/
download.html).
2.5. Determination of MMP-9, TIMP-1 and OPN levels in
mice and human serum samples
Levels of MMP-9, TIMP-1 and OPN were determined
using commercially available immunoassays kits. To deter-
mine levels in mouse serum, the mouse MMP-9 (total)
immunoassay kit (catalogue number MMPT90) and mouse
TIMP-1 immunoassay (catalogue number MTM100) were
purchased from R&D systems (Abingdon, United King-
dom), while the mouse OPN kit (code number 27351)
was purchased from IBL (Hamburg, Germany). The
immunoassay kits for detection in human serum were the
Human MMP-9 (total) immunoassay kit (catalogue
number DMP900), the Human TIMP-1 immunoassay kit
(catalogue number DTM100) and the Human OPN immu-
noassay kit (catalogue number DOST00) all purchased
from R&D systems. These kits used the quantitative
sandwich enzyme immunoassay technique where only free,
unbound forms of the biomarkers are detected. All exper-
iments were carried out in duplicates using the manufac-
turer’s instructions.
2.6. Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS), version 17. All data
sets were subjected to normality testing using the
Kolmogorov–Smirnov method. For comparisons between
means the Student’s t-test (two-tailed) was applied. Addi-
tionally, data on the independent study groups (DMD
and controls) were presented using descriptive statistics in
which the median value and interquartile range (IQR, the
statistical dispersion of the middle 50% of the data) were
calculated to show the distribution of the biomarker levels
for each group. Pearson’s Correlation was used for correla-
tion studies and data were analysed with a 95% conﬁdence
interval and P < 0.05 was considered signiﬁcant and P <
0.01 was considered highly signiﬁcant. For the longitudinal
DMD group, the statistical package from R2.9.2 was used
and the linear mixed-eﬀects model (lme4, version 0.999375-
38) was applied to determine the relationship of each bio-
marker with age and duration of corticosteroid therapy.
The ﬁxed and random eﬀects used in this model were as fol-
lows: for ﬁxed it was age and duration of corticosteroid
therapy and for random, it was the patient.3. Results
3.1. Gene expression analysis of Mmp9, Timp1 and Spp1 in
mouse quadriceps
As we had begun our study by selecting candidate bio-
markers from mdx gene expression data, we ﬁrst conﬁrmed
whether these mRNA expression changes were also present
in the mice used in our study. Whereas previously reported
studies on these biomarkers used sedentary mice [6,9], the
mdx and wt mice used for serum collection were subject
to exercise to augment the severity of the disease. We there-
fore compared the gene expression of Mmp9, Timp1 and
Spp1 (coding for OPN) between the study mice groups
(exercised mdx and exercised wt) and nonexercised mice
(mdx) using qPCR analysis. Fig. 1a, b and c show the gene
expression data of Mmp9, Timp1 and Spp1, respectively,
from the quadriceps of 16 week old, exercised mdx and
mdx compared to exercised wt. We observed no signiﬁcant
diﬀerence between the expression of these genes in the exer-
cised mdx and mdx group. There was, however, a signiﬁ-
cant diﬀerence between exercised wt and mdx. Although
gene expression in exercised mdx was much higher than
in exercised wt mice, this diﬀerence was not signiﬁcant
due to a higher standard deviation (SD) observed in the
exercised mdx group compared to the exercised wt and
mdx group.
3.2. Mouse serum levels of MMP-9, TIMP-1 and OPN
We then assessed serum from 8 and 14 week old exer-
cised mdx and exercised wt mice. At the age of 8 weeks, a
highly signiﬁcant diﬀerence was observed in the serum
MMP-9 levels between exercised wt and exercised mdx
mice. The serum MMP-9 levels in exercised mdx mice were
twofold higher than in exercised wt mice, with mean levels
of 41.8 ng/ml ± 10.5 (level ± SD) for exercised wt mice
and 86.52 ng/ml ± 21.07 for exercised mdx mice (Fig. 2a).
At the age of 14 weeks, levels of MMP-9 were still elevated
in exercised mdx mice (mean = 62.53 ng/ml ± 39.4), how-
ever this diﬀerence was not signiﬁcant when compared to
exercised wt mice at the similar age group (mean =
37.85 ng/ml ± 3.50). There were no signiﬁcant diﬀerences
in the serum levels at the diﬀerent time points for either
exercised wt or exercised mdx mice. However in exercised
mdx mice, a drop in serum levels of MMP-9 was noted
between 8 and 14 weeks.
The levels of TIMP-1 at 8 weeks were 3-fold higher in
exercised mdx mice (mean = 6.9 ng/ml ± 1.32) compared
to exercised wt mice (mean = 2.22 ng/ml ± 0.91), and this
diﬀerence was signiﬁcant (P < 0.01) (Fig. 2b). Although a
diﬀerence was observed in the TIMP-1 levels in 14 week
old mice, where exercised mdx mice (mean = 7.25 ng/
ml ± 1.55) had higher levels than exercised wt mice
(mean = 4.78 ng/ml ± 2.62), this diﬀerence was not signiﬁ-
cant. There was also no signiﬁcant diﬀerence in the levels of
TIMP-1 between 8 and 14 weeks for both strains.
Fig. 1. Gene expression analysis of (a) Mmp9, (b) Timp1 and (c) Spp1 in
exercised wt, exercised mdx and mdx. The bar charts show the mean levels
of gene expression for each biomarker and the error bars indicate the
standard deviation. One way ANOVA was used to determine diﬀerences
between groups and the Student’s t-test was applied to determine
signiﬁcant diﬀerences between two groups, where P < 0.01 is considered
highly signiﬁcant, and P < 0.05 is signiﬁcant. The number of mice per
group is ﬁve for wt and six for mdx.
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8 week old exercised mdx mice (mean = 3.44 ng/ml ± 0.54)
compared to exercised wt mice (mean = 2.62 ng/ml ± 0.59)
(Fig. 2c). At 14 weeks, the levels were similar for exercised
mdx (mean = 2.53 ng/ml ± 0.73) and exercised wt mice
(mean = 2.36 ng/ml ± 0.91).
CK levels were also determined for the 8 and 14 weeks
groups (Fig. 2d) and signiﬁcant diﬀerences were observed
between exercised wt and exercised mdx for mice at both
age groups. At 8 weeks, the CK levels for exercised wt werelower (mean = 142 U/L ± 100) than the CK levels for exer-
cised mdx (mean = 3900 U/L ± 1631). At 14 weeks, this
diﬀerence is smaller but still signiﬁcant as the CK levels
for exercised wt were 230 U/L ± 102 whereas they were
4773U/L ± 4024 for exercised mdx.
3.3. Serum levels of MMP-9, TIMP-1, and OPN in DMD
and control samples
We measured the serum levels of MMP-9, TIMP-1 and
OPN in serum samples of 63 DMD boys and 16 control
subjects (12 age-matched boys and 4 adult men) and statis-
tically compared the levels with Students t-test. The 12
boys and 4 adults in the healthy control group were
grouped together since there were no diﬀerences between
biomarker levels in young and adult subjects (data not
shown). As shown in Fig. 3a, serum MMP-9 levels were
signiﬁcantly higher in DMD (median level = 1185.34 ng/
ml, IQR = 966.56) compared to control samples (median
level = 73.22 ng/ml, IQR = 121.00) (P < 0.001). Similarly,
serum TIMP-1 (Fig. 3b) levels were signiﬁcantly higher in
DMD (median levels = 245.55 ng/ml, IQR = 69.57) com-
pared to control groups (median level = 164.77 ng/ml,
IQR = 62.45) (P < 0.01). The serum OPN levels, however,
were not signiﬁcantly diﬀerent between DMD (median lev-
els = 41.24 ng/ml, IQR = 33.74) and control groups (med-
ian level = 44.19 ng/ml, IQR = 30.69) (Fig. 3c).
Further stratiﬁcation of the DMD samples into ambulant
and nonambulant groups (Fig. 4) showed signiﬁcantly higher
levels for nonambulant compared to ambulant for MMP-9
(ambulant group median levels = 927.89, IQR = 885.60;
nonambulant group median levels = 1328.45, IQR =
822.95), while both groups were signiﬁcantly increased com-
pared to the control group. By contrast, similar levels were
observed in ambulant and nonambulant groups for TIMP-
1, which were both signiﬁcantly higher than in the control
group (Fig. 4b). OPN levels were similar for all three groups
(Fig. 4c).
3.4. Correlation between levels of MMP-9, TIMP-1, OPN,
age, steroid treatment and NSAA scores in DMD and control
groups
Pearson correlation analysis was applied to determine
the correlation coeﬃcient between the three biomarker lev-
els with other patient characteristics (age, years on steroid
treatment and NSAA scores) in the independent DMD
patient cohort (as observed from Table 3). MMP-9 levels
were positively correlated with age and duration of cortico-
steroid therapy (P < 0.01). There were however, no signiﬁ-
cant correlations observed between levels of MMP-9 and
TIMP-1, OPN or the functional scores, NSAA (ambulant
boys only). There was a signiﬁcant positive correlation
between age and duration of corticosteroid therapy
(P < 0.05) and although there was negative correlation
(correlation coeﬃcient of 0.241) between age and the
NSAA scores, the eﬀect was not signiﬁcant. Age dependent
Fig. 2. Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN and (d) CK in exercised wt and exercised mdx at 8 and 14 weeks. The bar charts show the mean
serum levels of each biomarker and the error bars indicate the standard deviation. One way ANOVA was used to determine diﬀerences between groups
and the Student’s t-test was applied to determine signiﬁcant diﬀerence between two groups, where P < 0.01 is considered highly signiﬁcant, and P < 0.05 is
signiﬁcant. The number of mice per group is ﬁve for wt and six for mdx.
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OPN showed negative correlation with NSAA scores (cor-
relation coeﬃcient of 0.309), however this eﬀect was not
signiﬁcant. In the control group, no signiﬁcant correlation
was observed between any of the variables (age, serum
MMP-9, TIMP-1 and OPN levels).3.5. Longitudinal analysis of MMP-9, TIMP-1 and OPN in
DMD patients
As nine patients were followed up longitudinally, there
was an opportunity to determine serum levels of these bio-
markers over time for the same group of patients. Fig. 4
shows the biomarker levels of the individual DMD patients
followed up between two and four and a half years. The lev-
els ofMMP-9 (Fig. 5a) increased with age whereas the levels
of TIMP-1 (Fig. 5b) did not demonstrate a consistent
increase with age. Interestingly, the levels of OPN (Fig. 5c)
seemed to decrease with age. To determine whether age
and duration of corticosteroid therapy had an eﬀect on bio-
marker levels, the linear mixed-eﬀects model analysis was
applied to the longitudinal data. We observed that MMP-9
shows a signiﬁcant linear relationship with age (t-stat =
2.17, P < 0.01) but duration of corticosteroid therapy does
not signiﬁcantly contribute to this relationship (t-stat =
0.63, P = 0.53). OPN levels show a signiﬁcant linear and
negative relationship with age (t-stat = 2.77, P < 0.01)and the duration of corticosteroid therapy does not contrib-
ute signiﬁcantly to this relationship (t-stat = 1.7, P = 0.1).4. Discussion
The potential biomarkers explored in this study, were
initially hinted at by recent ﬁndings in mdx mouse experi-
ments. Gene expression analysis of mdx muscle showed
that the Timp1 gene and the Spp1 gene (which encodes
OPN) were signiﬁcantly upregulated compared to muscles
of healthy mice [10], while other studies have shown that
both MMP-9 and OPN were elevated in serum of the
mdx mouse compared to wild-type [8,11]. MMP-9,
TIMP-1 and OPN are known to have a role as pro inﬂam-
matory markers [19,20] and in the absence of dystrophin in
mouse models, MMP-9 and OPN have been shown to have
an eﬀect in extra cellular matrix degeneration, inﬂamma-
tion and subsequent degeneration and regeneration of mus-
cle ﬁbres leading to ﬁbrosis [8,11]. Data from our 8 week
old exercised mice conﬁrmed the ﬁndings of these previous
studies. TIMP-1 levels remained elevated in 14 week old
exercised mdx mice, but MMP-9 and OPN levels appeared
to decrease with age. These latter observations were not in
agreement with previous reports [6,9], possibly as a conse-
quence of the exercise regimen we used with our mdx mice.
To examine whether our results diﬀered because mice used
in our study were subjected to forced exercise from the age
Fig. 3. Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN in DMD and
control samples. The median levels are indicated by the horizontal lines
bisecting the box plot, which shows the interquartile range. The upper and
lower limit of the bars show the maximum and minimum values
considered while the extreme values are indicated by s. Student’s t-test
was applied to determine signiﬁcant diﬀerence between the two groups.
Fig. 4. Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN in nonambulant,
ambulant and control samples. The median levels are indicated by the
horizontal lines bisecting the box plot, which shows the interquartile
range. The upper and lower limit of the bars show the maximum and
minimum values considered while the extreme values are indicated by s.
One way ANOVA was used to determine diﬀerences between groups and
the Student’s t-test was applied to determine signiﬁcant diﬀerence between
two groups.
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14 weeks) and sacriﬁce (16 weeks), we examined the geneexpression of these three biomarkers in exercised mdx
and nonexercised mdx mice. No signiﬁcant diﬀerences in
gene expression were observed between the exercised and
Table 3
Correlation between levels of biomarkers and clinical parameters of the independent DMD patient cohort.
MMP-9 TIMP-1 OPN Age Corticosteroid therapy
MMP-9 –
TIMP-9 0.187 (0.142) –
OPN 0.134 (0.293) 0.040 (0.757) –
Age 0.386** (0.002) 0.078 (0.545) 0.118 (0.358) –
Corticosteroid therapy 0.403** (0.001) 0.125 (0.329) 0.005 (0.971) 0.251* (0.047) –
NSAA Scores 0.028 (0.883) 0.025 (0.900) 0.309 (0.103) 0.241 (0.209) 0.145 (0.452)
() P-values.
* Correlation is signiﬁcant at P < 0.05.
** Correlation is signiﬁcant at P < 0.01.
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however observe that inter mouse variation was higher in
the exercised mdx group compared to the mdx and exer-
cised wt. It has been suggested that the beneﬁcial or delete-
rious eﬀect of exercise on dystrophic muscles depends on
the age of the animal at the start of exercise, the severity
of pathology, the intensity, and the duration and type of
training [21]. Although in this study these parameters were
similar in the exercised mdx group, the severity of the dys-
trophy for each mouse may be more variable, which could
contribute to the higher variation seen in this group.
Our results in humans are in line with the mouse data:
levels of MMP-9 and TIMP-1 are higher in DMD com-
pared to controls. We also observed that MMP-9 levels
were signiﬁcantly higher in older, nonambulant patients
compared to the younger, ambulant patients, suggesting
that there is an increase in MMP-9 levels with disease pro-
gression. Results of the longitudinal study supported this
observation as levels of MMP-9 increased with age for indi-
vidual patients. While this study reports on both MMP-9
and TIMP-1 levels in serum of DMD patients, gene expres-
sion analysis on DMD muscle tissue has indicated a role
for elevated TIMP1 and MMP2 in extra cellular matrix
modelling at early stages of disease development [9], which
makes it likely that MMP-9 and TIMP-1 are derived from
dystrophic muscles. An earlier study to detect inﬂamma-
tory proteins in muscles of symptomatic DMD patients
(5–12 years) and pre-symptomatic patients (infants)
showed that the transforming growth factor (TGF)-b path-
way was activated in the symptomatic group [22]. The
study by Li et al. 2009 suggested that MMP-9 increased
TGF-beta levels, which in turn exacerbated muscle degen-
eration in dystrophic mice [8]. A recent study comparing
plasma levels and muscle expression of TGF-b and
TIMP-1 in DMD, congenital muscular dystrophy (CMD)
and Becker muscular dystrophy (BMD) showed that these
markers were markedly elevated in DMD and CMD com-
pared to the less severe BMD [23]. Our data on serum levels
of MMP-9 and TIMP-1 conﬁrmed the ﬁndings of earlier
studies on the pathogenesis of DMD.
The Pearson correlation analysis also conﬁrmed a signif-
icant positive correlation between MMP-9 levels, age and
duration of corticosteroid treatment in the 63 DMD
patients. While the positive correlation between age andMMP-9 levels reﬂected the observation seen in the
nonambulant and ambulant patients, the correlation
between MMP-9 levels and duration of corticosteroid ther-
apy needs further analysis. The patient cohort in our study
was limited by the number of patients who were steroid
naı¨ve, and for patients that were on corticosteroid therapy,
age and duration of treatment was confounded, making it
diﬃcult to discriminate between disease progression due to
age and eﬀects of steroid treatment. From the limited stud-
ies available on MMP-9 levels and corticosteroid therapy,
one study on serum levels of patients with Graves ophthal-
mology and another on gene expression of MMP-9 in a
murine model showed that MMP-9 levels were lowered
after corticosteroid therapy [24,25] while another study of
asthmatic patients on corticosteroid therapy suggests that
MMP-9 levels do not diﬀer in steroid sensitive or resistant
patients [26]. There was however one study which showed a
short term increase in MMP-9 levels in patients with multi-
ple sclerosis on a high dose of intra-venous methyl-prednis-
olone (1000 mg/day), where MMP-9 levels were noted to
be signiﬁcantly elevated at day 10 before returning to
pre-treatment levels at day 20 [27]. In our study, the posi-
tive correlation between age and MMP-9 was further
strengthened by the results of the linear mixed-eﬀects anal-
ysis in the longitudinal DMD cohort as there was a signif-
icant and positive linear relationship between MMP-9
levels and age i.e. disease progression, and the duration
of steroid treatment did not contribute signiﬁcantly to this
relationship. Thus, based on our ﬁndings and information
available from the above mentioned literature, we suggest
that elevated MMP-9 levels are due to disease progression
rather than the eﬀect of corticosteroid treatment.
Although we observed TIMP-1 levels to be signiﬁcantly
higher in DMD compared to controls, there was no signif-
icant diﬀerence in levels between ambulant and nonambu-
lant groups or a signiﬁcant correlation with age. However,
due to the recent ﬁndings that plasma TIMP-1 levels are
lower in less severe BMD compared to DMD [23], the
reports that ratio of MMP-9 and TIMP-1 reﬂected the bal-
ance of pro and anti-inﬂammatory cytokines [28], and our
own observation that TIMP-1 levels remained elevated in
DMD patients, we suggest it is still useful to assess the
potential of TIMP-1 as a biomarker in larger and indepen-
dent cohorts from other clinical centres.
Fig. 5. Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN for the
longitudinal DMD patient cohort. The mean serum levels of nine DMD
patients were plotted over 2, 3 or 4 time points depending on patient
sample availability. The time points are represented as the patient’s age.
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DMD and control samples or between ambulant and
nonambulant groups. There was however a signiﬁcantlinear but negative relationship in the longitudinal cohort
for OPN and age. A recent study on DMD patients with
the less common G allele of the rs28357094 SPP1
promoter, which was associated to decreased OPN mRNA
expression levels, suggested that less SPP1 leads to more
muscle weakness, with lower grip strength and earlier age
for loss of ambulance [14]. As serum OPN levels were
not reported in that study, it would be of future interest
to know whether blood OPN levels were lowered in the
DMD patients carrying the less common G allele.
Current clinical trials on exon skipping and stop codon
read-through [29] include CK as a serum biomarker to
study the eﬀectiveness of treatment. While decreasing CK
levels can be a positive prognostic indicator in some dis-
eases (myocardiac infarction for example), in DMD
patients the role of CK as a prognostic biomarker is ques-
tionable. CK levels are markedly increased before signs and
symptoms of DMD are observed, conﬁrming the useful
diagnostic application at a very early stage of the disease.
However as mentioned earlier [2], declining CK levels in
DMD are associated to decrease in ambulatory skills and
disease progression. We suggest that MMP-9 and TIMP-
1 levels are potentially more useful biomarkers for response
to therapy, since they do not show this decreasing trend,
probably as a consequence of the continued inﬂammatory
response in DMD patients, even after substantial muscle
degeneration. Eﬀective therapy should reduce the degener-
ation-induced inﬂammatory response. Future studies have
to conﬁrm whether MMP-9 and TIMP-1 indeed decrease
after dystrophin restoration, and therefore are useful as
biomarkers to monitor therapeutic responses.
Due to their role in inﬂammation, cell migration, angio-
genesis and ﬁbrosis [28,30], elevated levels of MMP-9 and
TIMP-1 are not speciﬁc to DMD or muscle diseases. These
markers have been investigated for their role in cancers
(breast, bladder and pancreas), cardiovascular diseases
and in preeclampsia. In breast cancer for example,
MMP-9 is used as a marker for diagnosis and prognosis,
early detection and risk assessment, but also as an indicator
of tumour recurrence, metastatic spread, and response to
primary and adjuvant therapy [28]. In coronary artery dis-
ease, the ratio of MMP-9/TIMP-1 in serum was suggested
to be useful for progression of disease as it is reﬂective of
the balance between circulating pro and anti inﬂammatory
cytokines [30]. Hence, their diagnostic value for DMD per
se may be limited. However, based on our study in mice
and humans, we suggest to further evaluate MMP-9 and
TIMP-1 as valuable biomarkers in DMD for the monitor-
ing of disease progression and therapy eﬃcacy.
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